AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 251 min read$ARDX

Williams Laura A sold $41K of ARDX

Williams Laura A (Chief Patient Officer) sold 10,739 shares of ARDELYX, INC. (ARDX) at $3.86 across 4 trades on 2026-08-21.

Original reporting
SEC EDGAR · Williams Laura A
Published Aug 25, 2026, 11:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 25, 2026, 11:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ARDX
Neutral
high confidence
Mentioned
$ARDX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARDXNeutralLow
01

Why it matters

The sale is modest and does not materially affect Ardelyx's share structure.

02

Market read

Routine insider sale with limited trading relevance.

03

What to watch

Potential upcoming clinical trial results not yet disclosed.

Relevance 3/10Novelty 4/10Timing: filed 2026-08-25

Background

Form 4 filings disclose insider trades; investors monitor them for signals of confidence.

Company-level read

Ticker impact

$ARDXNeutralHigh confidence
Context

Chief Patient Officer Laura Williams sold 10,739 shares for $41.4K on 2026-08-21, reducing her stake to 367,456 shares.

Expected impact

No significant price impact expected.

Evidence & confidence

The sale size is small relative to market cap and insider holdings remain substantial.

Market effects

Sector

None; Ardelyx operates in a niche biotech segment with limited peer impact.

Regional

None; the transaction is company‑specific.

Global

None; no broader market effect.

Counterpoint

What could challenge this read

If insider confidence is low, the sale could signal concerns about upcoming data.

Key entities

  • Insider
    Laura Williams

    Chief Patient Officer of Ardelyx

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ARDX insider trading history →

Related articles

AUG 14
$ARDXMedAI 8/10

Ardelyx (ARDX) Q2 2026 Earnings Call Transcript

Ardelyx (ARDX) reported Q2 2026 product revenue of $118.1 million, up 31% year over year, driven by IBSRELA ($86.2 million, +33%) and XPHOZAH ($31.9 million, +27%). Net loss was $16.7 million. The company revised 2026 guidance to $350-$370 million for IBSRELA and $110-$120 million for XPHOZAH, citing payer hurdles.

fool.com6 min
AUG 7
$ARDXHighAI 9/10

Why is Ardelyx stock plunging today?

Ardelyx (ARDX) shares fell about 16% pre-open after the company reported Q2 2026 results that missed Wall Street on revenue and EPS and cut full-year guidance. Q2 total product revenue was $118.1M, net loss $16.7M (-$0.07/share). Ardelyx lowered 2026 IBSRELA revenue guidance to $350–$370M and withdrew a prior XPHOZAH long-term target.

investing.com4 min
AUG 6
$ARDXMed

ARDELYX, INC. (ARDX): Results of Operations and Financial Condition

ARDELYX, INC. (ARDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ardelyx Reports Second Quarter 2026 Financial Results and Provides Business Update Q2 2026 total product revenue of $118.1 million, reflecting 31% growth year-over-year IBSRELA Q2 2026 revenue growth of 33% year-over-year to $86.2 million XPHOZAH Q2 2026 revenue grow

SEC EDGAR 8-K5 min